Diabetes/Metabolism Research and Reviews Journal Impact Factor & Information

Publisher: Wiley

Journal description

Diabetes/Metabolism Research and Reviews is a print and electronic journal that publishes original research articles and reviews in diabetes and related areas of metabolism. The journal is dedicated to publishing papers with the shortest achievable lead times. The Editor-in-Chief and Co-Editors will consider original articles on the aetiology and pathogenesis of diabetes as well as treatment and management issues related to patient care. Areas of controversy are especially welcome. The reviews section serves the community of clinicians and researchers by providing an ongoing update of clinical and basic scientific advances in the most important areas of diabetes and metabolism.

Current impact factor: 3.55

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 3.553
2013 Impact Factor 3.593
2012 Impact Factor 2.968
2011 Impact Factor 3.373
2010 Impact Factor 3.094
2009 Impact Factor 2.762
2008 Impact Factor 3.149

Impact factor over time

Impact factor

Additional details

5-year impact 3.42
Cited half-life 6.50
Immediacy index 0.80
Eigenfactor 0.01
Article influence 1.08
Website Diabetes/Metabolism Research and Reviews website
Other titles Diabetes/metabolism research and reviews (Online), Diabetes/metabolism research and reviews, Diabetes metabolism research and reviews
ISSN 1520-7560
OCLC 39529047
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • On author's personal website, institutional repositories, arXiv, AgEcon, PhilPapers, PubMed Central, RePEc or Social Science Research Network
    • Author's pre-print may not be updated with Publisher's Version/PDF
    • Author's pre-print must acknowledge acceptance for publication
    • Non-Commercial
    • Publisher's version/PDF cannot be used
    • Publisher source must be acknowledged with citation
    • Must link to publisher version with set statement (see policy)
    • If OnlineOpen is available, BBSRC, EPSRC, MRC, NERC and STFC authors, may self-archive after 12 months
    • If OnlineOpen is available, AHRC and ESRC authors, may self-archive after 24 months
    • Publisher last contacted on 07/08/2014
    • This policy is an exception to the default policies of 'Wiley'
  • Classification
    ​ yellow

Publications in this journal

  • Ruifei Li · Rui Wang · Haixia Li · Sihao Sun · Meijuan Zou · Gang Cheng
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To assess the short-term and long-term effects of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes mellitus (T2DM) patients with renal impairment (RI). Methods: A meta-analysis of randomized clinical trials (RCTs) of DPP-4 inhibitor interventions in T2DM patients with RI was performed. PubMed, Embase, Cochrane Library and ClinicalTrials.gov were searched through the end of March 2015. RCTs were selected if (1) DPP-4 inhibitors were compared with a placebo or other active-comparators, (2) the treatment duration was ≥12 weeks and (3) data regarding changes in haemoglobin A1c (HbA1c), changes in fasting plasma glucose (FPG) or hypoglycaemia adverse events (AEs) were reported. Results: Of 790 studies, ten studies on eight RCTs were included. Compared with the control-group, DPP-4 inhibitors were associated with a greater HbA1c reduction in both the short-term [mean differences (MD) = -0.45, 95% confidence intervals (CI) (-0.57, -0.33), P < 0.0001] and long-term [MD = -0.33, 95% CI (-0.63, -0.03), P = 0.03] treatments. However, the long-term greater reduction in HbA1c with DPP-4 inhibitor treatment was only significant when the control treatment comprised placebo plus stable background treatment (SBT), but not glipizide plus SBT. DPP-4 inhibitors were associated with a greater FPG reduction [MD = -12.59, 95% CI (-22.01, -3.17), P = 0.009] over the short-term; however, this effect was not present over the long-term. Regarding the hypoglycaemia AEs assessment, the long-term treatment data indicated there was no increased risk of hypoglycaemia compared with placebo or active-controlled antidiabetic drugs. Conclusions: The present meta-analysis confirms that DPP-4 inhibitors are effective and equivalent to other agents in T2DM patients with RI. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 10/2015; DOI:10.1002/dmrr.2731
  • Gislaine Z Réus · Maria Augusta B Dos Santos · Helena M Abelaira · Stephanie E Titus · Anelise S Carlessi · Beatriz I Matias · Livia Bruchchen · Drielly Florentino · Andriele Vieira · Fabricia Petronilho · Luciane B Ceretta · Alexandra I Zugno · João Quevedo
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies have shown a relationship between diabetes mellitus (DM) and the development of major depressive disorder (MDD). Alterations in oxidative stress are associated with the pathophysiology of both DM and MDD. This study aimed to evaluate the effects of antioxidants n-acetylcysteine (NAC) and deferoxamine (DFX) on behavior and oxidative stress parameters in diabetic rats. To this aim, after induction of diabetes by a single dose of alloxan, Wistar rats were treated with NAC or DFX for 14 days and then depressive-like behavior was evaluated. Oxidative stress parameters were assessed in the prefrontal cortex (PFC), hippocampus, amygdala, nucleus accumbens (NAc) and pancreas. Diabetic rats displayed depressive-like behavior and treatment with NAC reversed this alteration. Carbonyl protein levels were increased in the PFC, hippocampus, and pancreas of diabetic rats, and both NAC and DFX reversed these alterations. Lipid damage was increased in the PFC, hippocampus, amygdala, and pancreas, however treatment with NAC or DFX reversed lipid damage only in the hippocampus and pancreas. Superoxide dismutase (SOD) activity was decreased in the amygdala, NAc, and pancreas of diabetic rats. In diabetic rats, there was a decrease in catalase (CAT) enzyme activity in the PFC, amygdala, NAc, and pancreas, but an increase in the hippocampus. Treatment with antioxidants did not have an effect on the activity of antioxidant enzymes. In conclusion, animal model of diabetes produced depressive-like behavior and oxidative stress in the brain and periphery. Treatment with antioxidants could be a viable alternative to treat behavioral and biochemical alterations induced by diabetes. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 10/2015; DOI:10.1002/dmrr.2732
  • Josta de Jong · Ester Garne · Ewa Wender-Ozegowska · Margery Morgan · Lolkje T W de Jong-van den Berg · Hao Wang
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Insulin analogues are commonly used in pregnant women with diabetes. It is not known if the use of insulin analogues in pregnancy is associated with any higher risk of congenital anomalies in the offspring compared with use of human insulin. Methods: We performed a literature search for studies of pregnant women with pregestational diabetes using insulin analogues in the first trimester and information on congenital anomalies. The studies were analyzed to compare the congenital anomaly rate among fetuses of mothers using insulin analogues with fetuses of mothers using human insulin. Results: Of 29 studies we included 1286 fetuses of mothers using short-acting insulin analogues with 1089 references of mothers using human insulin and 768 fetuses of mothers using long-acting insulin analogues with 685 references of mothers using long-acting human insulin (Neutral Protamine Hagedorn; NPH). The congenital anomaly rate was 4.84% and 4.29% among the fetuses of mothers using lispro and aspart. For glargine and detemir the congenital anomaly rate was 2.86% and 3.47% respectively. No studies on the use of insulin glulisine and degludec in pregnancy were found. There was no statistically significant difference in the congenital anomaly rate among fetuses exposed to insulin analogues (lispro, aspart, glargine or detemir) compared to those exposed to human insulin or NPH insulin. Conclusion: The total prevalence of congenital anomalies was not increased for fetuses exposed to insulin analogues. The small samples in the included studies provided insufficient statistical power to identify a moderate increased risk of specific congenital anomalies. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 10/2015; DOI:10.1002/dmrr.2730
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the last decade there has been an explosion in both the number of and knowledge about miRNAs associated with both type 1 and type 2 diabetes. Even though we are presently in the initial stages of understanding how this novel class of posttranscriptional regulators are involved in diabetes, recent studies have demonstrated that miRNAs are important regulators of the islet transcriptome, controlling apoptosis, differentiation, proliferation, as well as regulating unique islet and beta-cell functions and pathways such as insulin expression, processing and secretion. Furthermore, a large number of miRNAs have been linked to diabetogenic processes induced by elevated levels of glucose, free fatty acids and inflammatory cytokines. Thus, miRNAs are novel therapeutic targets with the potential of protecting the beta-cell, and there is proof-of-principle that miRNA antagonists, so called antagomirs, are effective in vivo for other disorders. miRNAs are exported out of cells in exosomes, raising the intriguing possibility of cell-to-cell communication between distant tissues via miRNAs and that miRNAs can be used as biomarkers of beta-cell function, mass and survival. The purpose of this review is to provide a status on how miRNAs control beta-cell function and viability in health and disease. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2719
  • [Show abstract] [Hide abstract]
    ABSTRACT: Foot problems complicating diabetes are a source of major patient suffering and societal costs. Investing in evidence-based, internationally appropriate diabetic foot care guidance is likely among the most cost-effective forms of healthcare expenditure, provided it is goal-focused and properly implemented. The International Working Group on the Diabetic Foot (IWGDF) has been publishing and updating international Practical Guidelines since 1999. The 2015 updates are based on systematic reviews of the literature, and recommendations are formulated using the Grading of Recommendations Assessment Development and Evaluation (GRADE) system. As such, we changed the name from "Practical Guidelines" to "Guidance". In this article we describe the development of the 2015 IWGDF Guidance documents on prevention and management of foot problems in diabetes. This Guidance consists of five documents, prepared by five working groups of international experts. These documents provide guidance related to foot complications in persons with diabetes on: prevention; footwear and offloading; peripheral artery disease; infections; and, wound healing interventions. Based on these five documents, the IWGDF Editorial Board produced a summary guidance for daily practice. The resultant of this process, after review by the Editorial Board and by international IWGDF members of all documents, is an evidence-based global consensus on prevention and management of foot problems in diabetes. Plans are already under way to implement this Guidance. We believe that following the recommendations of the 2015 IWGDF Guidance will almost certainly result in improved management of foot problems in persons with diabetes and a subsequent worldwide reduction in the tragedies caused by these foot problems. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2694
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Elevated serum uric acid (SUA) level is often observed in type 2 diabetes or cancer progression. This study aimed to investigate the association between the SUA, cancer incidence and mortality in Chinese patients with type 2 diabetes. Methods: A total of 8,274 patients with type 2 diabetes from the Shanghai Diabetes Registry (SDR) participated. The follow-up rate was 85.4%. All subjects were divided into 4 groups according to the SUA concentration: group 1 (1.0 mg/dl ≤ SUA < 3.0 mg/dl), group 2 (3.0 mg/dl ≤ SUA <5.0 mg/dl), group 3 (5.0 mg/dl ≤ SUA < 7.0 mg/dl), and group 4 (SUA ≥ 7.0 mg/dl). The primary outcome was the first diagnosis of any cancer. The secondary outcome was all-cause mortality. A Cox proportional hazards model was used to estimate the relative risks of cancer and death. Results: 137 men and 115 women had cancer by the end of the study. In female, group 1 had the lowest incidence rate of cancer at 30.3 cases per 10,000 person-years, followed by group 2 (48.2). The cancer incidence rates in groups 3 (80.4) and 4 (100.8) were significantly higher than in group 2 (P < 0.05). No significant differences were observed in the incidence of cancer in male (P = 0.76). The risks of overall mortality and death from cancer were not significantly different among the different SUA groups in either sex (Pmale = 0.480, Pfemale = 0.075). Conclusion: In Chinese female diabetic patients, the incidence of cancer increased with SUA levels. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2724
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Recent work in Pima Indians, a population with high rates of obesity and type 2 diabetes mellitus (T2DM), demonstrated HLA haplotype DRB1*02 carriers have an increased acute insulin response and decreased risk for the development of T2DM, implicating loss of self-tolerance in the pathogenesis of T2DM. Advances in genomic sequencing have made T-cell receptor (TCR) repertoire analysis a practical mode of investigation. Methods: High-throughput sequencing of TCR complementarity determining region 3 (CDR3) was carried out in male Pima Indians with normal glucose regulation (NGR; n = 11; age = 31 ± 8y; %fat = 30.2 ± 8.7%)) and the protective DRB1*02 haplotype versus those with type 2 diabetes mellitus without DRB1*02 (n = 7; age = 34 ± 8y; %fat = 31.2 ± 4.7%). Findings were partially replicated in another cohort by assessing the predictive ability of TCR variation on risk of T2DM in Pima Indian men (n = 27; age = 28.9 ± 7.1y; pfat = 28.8 ± 7.1%) and women (n = 20; age = 29 ± 7.0y; pfat = 37.1 ± 6.8%) with baseline NGR but without the protective haplotype who were invited to follow-up examinations as frequently as every 2 years where diabetes status was assess by a 75 g OGTT. Of these subjects, 13 developed diabetes. Results: TCR CDR3 length was shorter in those with T2DM, and a one-nucleotide decrease in CDR3 length was associated with a nearly 3-fold increase in risk for future diabetes. The frequency of one variable gene, TRBV7-8, was higher in those with T2DM. A one percent increase in TRBV7-8 frequency was associated with a greater than 3-fold increase in diabetes risk. Conclusions: These results indicate T-cell autoimmunity may be an important component in progression to T2DM in Pima Indians. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2720
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: We investigated the rate of severe hypoglycemic events and confounding factors in patients with type-2-diabetes treated with sulfonylurea (SU) at specialized diabetes centers, documented in the German/Austrian DPV-Wiss-database. Methods: Data from 29,485 SU-treated patients were analyzed (median[IQR] age 70.8[62.2-77.8]yrs, diabetes-duration 8.2[4.3-12.8]yrs). The primary objective was to estimate the event-rate of severe hypoglycemia (requiring external help, causing unconsciousness/coma/convulsion and/or emergency.hospitalization). Secondary objectives included exploration of confounding risk-factors through group-comparison and Poisson-regression. Results: Severe hypoglycemic events were reported in 826(2.8%) of all patients during their most recent year of SU-treatment. Of these, n = 531(1.8%) had coma, n = 501(1.7%) were hospitalized at least once. The adjusted event-rate of severe hypoglycemia [95%CI] was 3.9[3.7-4.2] events/100 patient-years (coma: 1.9[1.8-2.1]; hospitalization: 1.6[1.5-1.8]). Adjusted event-rates by diabetes-treatment were 6.7 (SU + insulin), 4.9 (SU + insulin + other OAD), 3.1 (SU + other OAD), and 3.8 (SU only). Patients with ≥1 severe event were older (p < 0.001) and had longer diabetes-duration (p = 0.020) than patients without severe events. Participation in educational diabetes-programs and indirect measures of insulin-resistance (increased BMI, plasma-triglycerides) were associated with fewer events (all p < 0.001). Impaired renal function was common (N = 3,113 eGFR ≤30 mL/min) and associated with an increased rate of severe events (≤30 mL/min: 7.7; 30-60 mL/min: 4.8; >60 mL/min: 3.9). Conclusions: These real-life data showed a rate of severe hypoglycemia of 3.9/100 patient-years in SU-treated patients from specialized diabetes centers. Higher risk was associated with known risk-factors including lack of diabetes-education, older age, and decreased eGFR, but also with lower BMI and lower triglyceride-levels, suggesting that SU-treatment in those patients should be considered with caution. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2722
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: We investigated whether parental history of type 2 diabetes mellitus (T2D) is associated with age, lifestyle, anthropometric factors, and clinical severity at the time of T2D diagnosis. Methods: We conducted a cross-sectional study based on the Danish Centre for Strategic Research in Type 2 Diabetes cohort. We examined the prevalence ratios (PR) of demographic, lifestyle, anthropometric and clinical factors according to parental history, using Poisson regression adjusting for age and gender. Results: Of 2,825 T2D patients, 34% (N = 964) had a parental history of T2D. Parental history was associated with younger age at diagnosis [adjusted (a)PR 1.66, 95% confidence interval (CI): 1.19, 2.31) for age <40 years; aPR 1.36 (95% CI: 1.24, 1.48) for ages 40-59 years] and with higher baseline fasting plasma glucose [≥7.5 mmol/L, aPR 1.47 (95% CI: 1.20, 1.80)], and also tended to be associated with lower beta cell function. In contrast, patients both with and without a parental history had similar occurrence of central obesity [91% vs 91%], weight gain ≥30 kg since age 20 [52% vs. 53%], and lack of regular physical activity [60% vs. 58%]. Presence of diabetes complications or comorbidities at T2D diagnosis was not associated with parental history. Conclusions: The lack of an association between parental history and adverse lifestyle factors indicates that T2D patients do not inherit a particular propensity for overeating or inactivity, whereas patients with a parental history may have more severe pancreatic beta cell dysfunction at diagnosis. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2721
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oxidative stress (OS) refers to an imbalance between potentially harmful free radicals and the body's mechanisms to efficiently detoxify them in favor of the free radicals. Consequently, excess free radicals can attack to and damage a wide range of biomolecules including proteins, lipids and nucleic acids. Antioxidant mechanisms of the body are under the influence of genetic and environmental (including dietary) factors. Diabetes is the most common metabolic disorder all around the world. A huge body of evidence indicates a role for OS in development of many human diseases including diabetes. In this article, the latest information on the possible links of OS with diabetes development, control and complications as well as the newest results of antioxidant supplementation trials is reviewed. In continue, the possible role of vitamin D, as a newly recognized antioxidant, in diabetes is discussed. Finally, concluding remarks and pivotal issues for future studies are presented. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2718
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Nonalcoholic fatty liver disease (NAFLD) has a high prevalence in patients with type 2 diabetes mellitus (T2DM). In this study, we sought to provide a comprehensive assessment regarding the effects of anti-diabetic agents on NAFLD in patients with T2DM. Methods: MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) with different anti-diabetic agents in T2DM. Observational trials were also recruited to expand our exploration. Hepatic fat content (HFC) and liver histology were evaluated as primary outcomes. Pooled estimates were calculated using a fixed effect model. Results: 1,196 participants in nineteen RCTs and fourteen non-randomized studies were included. Evidence from RCTs and observational studies suggested that greater HFC reduction and improved liver histology were seen in TZDs for 12-72 weeks; GLP-1R agonists had beneficial effects on HFC after 26-50 weeks intervention, and insulin/metformin combination with 3-7 months improved HFC. Initiating metformin or dapagliflozin showed no benefit on HFC or liver histology in 16-48 weeks. Besides, nateglinide for 18 months was reported in a small sample-size RCT to ameliorate HFC and liver histology. Sitagliptin therapy of one year also provided benefit on nonalcoholic steatohepatitis score in an observational study. Conclusions: For T2DM with NAFLD, administrating TZDs and GLP-1R agonists seems to provide more identified advances in attenuating HFC. Further RCTs are warranted to assess the efficacy of various hypoglycemic agents on clinical outcomes associated with NAFLD in T2DM. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2713
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Type 2 diabetes mellitus (T2DM) is closely associated with elevated body iron stores. The hormone hepcidin is the key regulator of iron homeostasis. Inadequately low hepcidin levels were recently reported in subjects with manifest T2DM. We investigated whether alterations of hepcidin levels precede the manifestation of T2DM and predict T2DM development independently of established risk conditions. Methods: This prospective population-based study included 675 subjects aged 50 to 89 years, 51.9% of whom were female. Hepcidin levels were measured by gold standard tandem mass spectrometry. Diabetes was diagnosed according to American Diabetes Association criteria and incident diabetes was recorded between baseline in 2000 and 2010. Results: The baseline hepcidin-to-ferritin ratio in subjects that subsequently developed diabetes during follow-up was reduced on average by 29.8% as compared to subjects with normal glucose tolerance (95% confidence interval, -50.7% to -0.2%; P = 0.049). Under adjustment for age, sex, and serum ferritin, higher hepcidin levels were associated with reduced risk of incident diabetes (hazard ratio per 1-unit higher log2 hepcidin, 0.80; 95% confidence interval, 0.64 to 0.98; P = 0.035; 33 events). Additional adjustment for established diabetes risk factors and determinants of hepcidin concentration did not appreciably change these results (HR, 0.81; 95% CI, 0.66 to 0.99). In line, inadequately low hepcidin levels were also detected in subjects with prevalent T2DM (n = 76). Conclusions: Hepcidin levels that are inadequately low in relation to body iron stores are an independent predictor for incident T2DM and may contribute to diabetes-related tissue iron overload. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2711
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Timely initiation and titration of basal insulin adding on oral antidiabetic drug (OAD)s contribute to better glycemic control. However, implementation of basal-supported oral therapy (BOT) in China is not yet clear. This nationwide, prospective, 12-week observational study was designed to explore the current status of BOT in patients with type 2 diabetes in China. Methods: Type 2 diabetic patients with inadequate glycemic control on OAD(s) who were to start BOT with insulin glargine at outpatient clinics were enrolled from 134 hospitals in China. Both the decision to initiate basal insulin and insulin dose adjustment were at the physician's discretion. Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) were measured, and the starting dose of insulin were recorded at baseline. Self-monitored fasting capillary blood glucose (FBG) and the adjusting dose of insulin were collected during the study. Results: A total of 11,192 out of 13,259 enrolled patients finished the 12-week study. FPG and HbA1c at BOT initiation were 11.2 mmol/L and 9.4%, respectively, with insulin glargine started at 0.190 IU/kg/day. Insulin dose titration was not active, represented by1.8 IU increased within 12 weeks. Fifty-nine percentages of the patients achieved FBG ≤ 7.0 mmol/L. More patients achieved the glucose target in the group with lower baseline FPG level. Notable geographical differences of physicians' treatment habits in the current management of BOT were also observed. Conclusions: A great gap between everyday clinical practice and guideline exists in China, reflecting by the delayed initiation, slow dose titration and geographical differences of BOT management. A concrete guideline of BOT management is needed in the clinical application. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2709
  • [Show abstract] [Hide abstract]
    ABSTRACT: The expert panel on diabetic foot infection (DFI) of the International Working Group on the Diabetic Foot conducted a systematic review seeking all published reports relating to any type of treatment for infection of the foot in persons with diabetes published as of 30 June 2014. This review, conducted with both PubMed and EMBASE, was used to update an earlier one undertaken on 30 June 2010 using the same search string. Eligible publications included those that had outcome measures reported for both treated and a control populations that were managed either at the same time, or as part of a before and after case design. We did not include studies that contained only information related to definition or diagnosis, but not treatment, of DFI. The current search identified just seven new papers meeting our criteria that were published since the 33 identified with the previous search, making a total of 40 papers from the world literature. The identified papers included 37 randomised controlled trials (RCTs) and 3 cohort studies with concurrent controls, and included studies on the use of surgical procedures, topical antiseptics, negative pressure wound therapy and hyperbaric oxygen. Among the studies were 15 RCTs that compared outcomes of treatment with new antibiotic preparations compared with a conventional therapy in the management of skin and soft tissue infection. In addition, 10 RCTs and one cohort study compared different treatments for osteomyelitis in the diabetic foot. Results of comparisons of different antibiotic regimens generally demonstrated that newly introduced antibiotic regimens appeared to be as effective as conventional therapy (and also more cost-effective in one study), but one study failed to demonstrate non-inferiority of a new antibiotic compared to a standard agent. Overall, the available literature was both limited in both the number of studies and the quality of their design. Thus, our systematic review revealed little evidence upon which to make recommendations for treatment of DFIs. There is a great need for further well-designed trials that will provide robust data upon which to make decisions about the most appropriate treatment of both skin and soft tissue infection (SSTI) and osteomyelitis in diabetic patients. This article is protected by copyright. All rights reserved.
    Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2706
  • Diabetes/Metabolism Research and Reviews 09/2015; DOI:10.1002/dmrr.2695